3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
2
Stroke
1
Recurrence
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Communication
1
Colorectal Neoplasms
1
Caregiver Burden
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Brain Neoplasms
1
Brain Injuries, Traumatic
1
Brain Injuries
1
Advanced Malignant Solid Neoplasm
1
Interventions
Cyclophosphamide
10
fludarabine
7
pomalidomide
5
pembrolizumab
5
Dexamethasone
5
daratumumab
4
obinutuzumab
3
glofitamab
3
fludarabine phosphate
3
abemaciclib
3
Rituximab
3
Melphalan
3
Immunotherapy, Adoptive
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
pirtobrutinib
2
palbociclib
2
cemiplimab
2
blinatumomab
2
Temozolomide
2
Sirolimus
2
Oxaliplatin
2
Nivolumab
2
Mesna
2
Letrozole
2
Injections
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Palliative Care
×
30 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled